促血栓基因型与身高对静脉血栓栓塞症风险的联合效应:特罗姆瑟研究
在特罗姆瑟研究(1994-2012年随访)中,676例 incident VTE 病例与1842例年龄加权亚队列被纳入,检测5个促血栓单核苷酸多态性(SNP)并计算 de Haan 5-SNP 评分。身高≥178 cm者较≤165 cm者 VTE 风险约高两倍(HR 2.03;95%CI 1.51-2.73);但促血栓基因型与高身材联合未产生额外 VTE 风险。
要点
- 身高≥178 cm者 VTE 风险较≤165 cm者升高(HR 2.03;95%CI 1.51-2.73)。
- 促血栓基因型与高身材联合未导致额外 VTE 风险。
- ≥4个风险等位基因且身高≥178 cm者较≤165 cm且0-1个风险等位基因者 VTE 风险升高(HR 2.08;95%CI 1.24-3.52)。
核心结论
- 与肥胖不同,促血栓基因型的存在并未在高身材受试者中导致额外的 VTE 风险。
研究设计与样本
- 研究基于特罗姆瑟研究(队列随访:1994-2012年),纳入 incident VTE 病例676例和随机选取的年龄加权亚队列1842例。
- 对 rs6025(凝血因子V Leiden)、rs1799963(凝血酶原)、rs8176719(ABO血型)、rs2066865(纤维蛋白原-γ)和 rs2036914(凝血因子IX)进行 DNA 基因分型。
- 按风险等位基因类别(de Haan 5-SNP 评分:0-1、2-3、≥4)和身高百分位(<40th、40th-80th、>80th)计算年龄和性别校正的风险比(HR)。
主要发现
- 身高≥178 cm者 VTE 风险较身高≤165 cm者升高(HR 2.03;95%CI 1.51-2.73)。
- VTE 风险随风险等位基因类别增加而升高。
- 高身材与风险等位基因(单个 SNP 或风险评分)联合未导致额外 VTE 风险。
- ≥4个风险等位基因且身高≥178 cm者较≤165 cm且0-1个风险等位基因者 VTE 风险升高(HR 2.08;95%CI 1.24-3.52)。
关键数值与推荐
- 身高≥178 cm者 VTE 风险较身高≤165 cm者升高(HR 2.03;95%CI 1.51-2.73)。
- ≥4个风险等位基因且身高≥178 cm者较≤165 cm且0-1个风险等位基因者 VTE 风险升高(HR 2.08;95%CI 1.24-3.52)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Body height and prothrombotic genotypes are associated with risk of venous thromboembolism (VTE). The joint effect of prothrombotic genotypes and tall stature on VTE risk is scarcely investigated. We investigated the joint effect of prothrombotic genotypes and tall stature on VTE risk. Prothrombotic genotypes did not yield excess risk of VTE in subjects with a tall stature. SUMMARY: Background Studies have reported synergistic effects of prothrombotic single-nucleotide polymorphisms (SNPs) and obesity on the risk of venous thromboembolism (VTE). Tall stature is associated with an increased VTE risk, but the joint effect of prothrombotic genotypes and tall stature on the VTE risk is unknown. Aims To investigate the joint effects of prothrombotic genotypes and tall stature on the VTE risk. Methods Cases with incident VTE (n = 676) and a randomly selected age-weighted subcohort (n = 1842) were sampled from the Tromsø study (cohort follow-up: 1994-2012). DNA was genotyped for rs6025 (factor V Leiden), rs1799963 (FII), rs8176719 (ABO blood group), rs2066865 (fibrinogen-γ), and rs2036914 (FIX). Age-adjusted and sex-adjusted hazard ratios (HRs) of VTE were calculated by categories of risk alleles (de Haan 5-SNP score: 0-1, 2-3, and ≥ 4) and body height (< 40th, 40th-80th and > 80th percentiles). Results The VTE risk increased by increasing category of body height, and subjects with height ≥ 178 cm had a two-fold higher VTE risk (HR 2.03; 95% confidence interval [CI] 1.51-2.73) than those with height ≤ 165 cm. The VTE risk also increased across categories of risk alleles. However, the combination of a tall stature and risk alleles, either individual SNPs or risk score, did not result in an excess VTE risk. Subjects with four or more risk alleles and height ≥ 178 cm had a two-fold (HR 2.08; 95% CI 1.24-3.52) higher VTE risk than subjects ≤ 165 cm with no risk allele or one risk allele. Conclusions In contrast to obesity, the presence of prothrombotic genotypes did not result in an excess VTE risk in subjects with a tall stature.
引用
- Horvei LD, Braekkan SK, Smith EN, et al. Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study. J Thromb Haemost. 2017. PMID: 29094466. doi:10.1111/jth.13892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。